Skip to main content

Table 1 Patient, tumour characteristics and disease stages for 53 breast cancers on 50 patients

From: Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments

Age [years] Median 68
  Range 36-88
T pT1mi 1 (2%)
  pT1a 6 (11%)
  pT1b 11 (21%)
  pT1c 20 (38%)
  pT2 15 (28%)
N pN0 49 (92%)
  pN1 4 (8%)
Histology IDC 41 (77%)
  ILC 10 (19%)
  Other Invasive 2 (4%)
  DCIS 0 (0%)
Grading I 10 (19%)
  II 38 (72%)
  III 5 (9%)
Estrogen Receptors Positive 49 (92%)
  Negative 4 (8%)
Progesterone Receptors Positive 46 (87%)
  Negative 7 (13%)
Her-2/neu Overexpressed 1 (2%)
  Not overexp. 52 (98%)
Ki-67 ≥20 3 (6%)
  <20 50 (94%)
Disease Stage 0 0 (0%)
  I 43 (81%)
  II 10 (19%)
  1. IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; DCIS: ductal carcinoma in situ.